The Listing of the Claims

- 1. (Original) A method for determining tissue factor (TF) activity in a sample suspected to contain TF, comprising: (a) combining TF and a molar excess of factor VIIa (fVIIa) to produce a TF/fVIIa enzyme complex; and (b) detecting enzymatic activity of the complex using a fluorogenic or chromogenic substrate.
- 2. (Original) The method of claim 1, wherein the substrate is a compound of the formula: or a pharmaceutically acceptable non-toxic salts thereof; wherein R₁ is hydrogen, straight or branched chain lower alkyl having 1-6 carbon atoms optionally substituted with C₁-C₆ alkoxy, straight or branched chain alkenyl having 2-8 carbon atoms, straight or branched chain alkynyl having 2-8 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkylcycloalkyl where the alkyl portion has 1-6 carbon atoms, cycloalkylakyl where the alkyl portion has 1-6 carbon atoms, or phenylalkyl where the alkyl portion is straight or branched chain alkyl having 1-6 carbon atoms, or a group of the formula R5 represents hydrogen or an amino acid side chain; and R4 is hydroxy, C₁-C₆ alkoxy, an amino acid or a peptide residue; R₂ is hydrogen, straight or branched chain lower alkyl having 1-6 carbon atoms, straight or branched chain alkenyl having 2-8 carbon atoms, straight or branched chain alkynyl having 2-8 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkylcycloalkyl where the alkyl portion has 1-6 carbon atoms, or phenylalkyl where the alkyl portion is straight or branched chain alkyl having 1-6 carbon atoms, or a group of the formula R₅ represents hydrogen or an amino acid side chain; and R₄ is hydroxy, C₁-C₆ alkoxy, an amino acid or peptide residue; or NR₁R₂ forms a nitrogen heterocycle; and R₃ is an amino acid or a peptide residue.
- 3. (Original) The method of claim 1, where the substrate is a chromogenic substrate.
- 4. (Currently Amended) The method of claim 3, where the chromogenic substrate is a pare-Nitroaniline-based substrate para-nitroaniline.
- 5. (Original) The method of claim 1, further comprising (c) generating a numerical value associated with the enzymatic activity of the sample and (d) comparing the numerical value with a standard curve of TF-dependent enzymatic activity.

- 6. (Original) The method of claim 5, wherein the standard curve is generated by quantifying TF-dependent enzymatic activity of the TF/fVIIa complex in samples with known concentrations of TF.
- 7. (Original) The method of claim 6, wherein the TF is native human tissue factor.
- 8. (Original) The method of claim 6, wherein TF source is brain tissue, placenta, endothelial cells, tissue extract, plasma, cell extract, synthetic or naturally derived thromboplastin, or recombinant human tissue factor.
- 9. (Original) The method of claim 6, wherein the fVIIa is native human factor VIIa or recombinant factor VIIa.
- 10. (Original) The method of claim 6, wherein the TF and the fVIIa are not of human origin.
- 11. (Original) The method of claim 6, wherein the concentration of TF is from 0.1 pM to 1 mM.
- 12. (Original) The method of claim 6, wherein the reaction mixture contains divalent metal ion or a metal ion chelator.
- 13. (Original) The method of claim 12, wherein the divalent metal ion is calcium ion, magnesium ion or manganese ion.
- 14.(Original) The method of claim 12, wherein the metal ion chelator is ethylenediamimetetraacetic acid (EDTA) or ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA).
- 15. 29. (Canceled)